Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel

The effect of semaglutide, a once-weekly human glucagon-like peptide-1 (GLP-1) analog in development for type 2 diabetes (T2D), on the bioavailability of a combined oral contraceptive was investigated. Postmenopausal women with T2D (n = 43) on diet/exercise ± metformin received ethinylestradiol (0.0...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapitza, Christoph, Nosek, Leszek, Jensen, Lene, Hartvig, Helle, Jensen, Christine B, Flint, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418331/
https://www.ncbi.nlm.nih.gov/pubmed/25475122
http://dx.doi.org/10.1002/jcph.443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418331/
https://www.ncbi.nlm.nih.gov/pubmed/25475122
http://dx.doi.org/10.1002/jcph.443

Ejemplares similares